Get the Latest Investment Ideas Delivered Straight to Your Inbox.

News Update

TICKERS: VIV

Livestock Feed Developer Partners to Initiate Product Sales in the U.S.
News Update

Source:

The arrangement represents this Canadian life sciences firm's entrée into a significant market.

Avivagen Inc. (VIV:TSX.V) announced in a news release it signed a partnership agreement with CSA Animal Nutrition for it to sell and distribute Avivagen's OxC-beta livestock feed in the United States. CSA also will "coordinate commercial-scale validation research with potential customers."

"OxC-beta™ Livestock is a proprietary product shown to be effective and economic in replacing the antibiotics commonly added to livestock feeds," the company noted.

Based in Ohio, CSA provides nutrition solutions and services for meat, milk and egg producers, feed manufacturers and nutrition consultants. With more than 20 years' experience, the company has numerous relationships in the United States.

The partnership with CSA gives Avivagen access to 20% of the global feed market for poultry, swine and dairy cattle, the release noted.

"We're very excited to be entering into this important relationship that will bring OxC-beta to this crucial market and allow for the sale of OxC-beta within the United States," said Kym Anthony, chairman and interim CEO of Avivagen. "With their extensive technical experience and relationships and ability to access the US livestock and poultry markets, CSA represents a strong partner for Avivagen. The timing is good given the regulatory process in the US is now completed and we look to add sales and distribution networks in new markets to significantly drive our sales."

According to Avivagen, "As an independent firm, CSA has the flexibility and expertise to reach a variety of customers across numerous species, from integrated commercial livestock and poultry production companies and young animal product manufacturers to premix blenders, thereby enhancing the potential adoption and sale of OxC-beta."

[NLINSERT]

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a billboard sponsor of Streetwise Reports: Avivagen. Click here for important disclosures about sponsor fees. As of the date of this article, an affiliate of Streetwise Reports has a consulting relationship with Avivagen. Please click here for more information.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this article, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of Avivagen, a company mentioned in this article.




Want to read more about Nutraceuticals and Agriculture investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe